Identification of Asporin as a Potential Mediator of Skeletal Fluorosis via the TGF-β1/Smad2/3 Axis: Evidence from Population, Animal, and Cellular Models

For centuries, doctors have known that too much fluoride in drinking water can damage bones, a condition known as skeletal fluorosis. In areas where the water naturally contains high levels of this mineral, people often develop bones that are harder but more brittle, prone to fractures and pain. The body's skeleton is a living structure that constantly rebuilds itself through a careful balance between two types of cells: builders that lay down new bone and recyclers that remove old bone. When this balance tips, disease follows. In skeletal fluorosis, the builders become overactive, piling up bone in a disorganized way, while the recyclers struggle to keep up. Scientists have long suspected that a specific chemical signaling system inside these cells is responsible for this overactivity, but the exact chain of events triggering the problem has remained unclear. Understanding this mechanism is crucial because it could reveal new ways to diagnose the disease early or develop treatments to stop the damage before it becomes severe.

A team of researchers from Harbin Medical University in China recently set out to trace this chain of events, moving from the microscopic world of cells to the real-world experience of people living in affected areas. They focused on a protein called asporin, a substance found in the space between cells that helps organize the building blocks of bone. The researchers wanted to know if fluoride exposure causes the body to produce too much of this protein, and if that excess production drives the bone disease. To find the answer, they built a complete picture using three different approaches: they studied rats exposed to varying amounts of fluoride in their water, they tested human bone cells in a laboratory, and they analyzed blood samples from hundreds of people living in a region of China where fluorosis is common.

In the laboratory, the team began by exposing human bone cells to different concentrations of fluoride, ranging from levels found in normal water to levels found in the most heavily affected areas. They observed that when the cells were exposed to moderate to high levels of fluoride, they became more active and started producing significantly more asporin. The cells also showed signs of ramping up their bone-building machinery. The researchers then looked deeper into the cell's internal communication system. They found that fluoride triggered a specific pathway, a chain of chemical messages that starts with a signal called TGF-beta1 and travels through molecules known as Smad2 and Smad3. This pathway acts like a switch that turns on the production of asporin. To prove that this pathway was the key, the researchers used a technique to temporarily silence the Smad3 molecule. When they did this, the fluoride could no longer trigger the overproduction of asporin, and the cells stopped behaving as if they were in a state of disease. This experiment confirmed that the fluoride was hijacking this specific signaling route to force the cells to make too much asporin, which in turn drove the abnormal bone growth.

The team then moved to a living model to see if these findings held true in a whole organism. They gave groups of rats water containing different amounts of fluoride for twelve weeks. The rats that drank water with higher fluoride levels developed the same bone changes seen in human patients: their bone structure became disordered, and their bone density changed. When the researchers examined the bone tissue of these rats, they found that the levels of asporin had risen dramatically in direct proportion to the amount of fluoride the animals had consumed. The more fluoride the rats drank, the more asporin their bones produced. This confirmed that the mechanism observed in the petri dish was also happening inside a living body, linking the chemical exposure directly to the protein's surge.

Finally, the researchers took their investigation to the human population. They recruited nearly 750 adults from a region in Shanxi Province known for high fluoride levels in the water. They divided the participants into two groups: those diagnosed with skeletal fluorosis and those without the disease. They measured the levels of fluoride in the participants' urine and the levels of asporin and other bone markers in their blood. The results were revealing. While the researchers found that people with fluorosis had higher levels of fluoride in their urine, the levels of asporin in their blood did not show a clear, direct link to whether someone had the disease or how severe it was. This suggests that asporin might not be a reliable standalone test to diagnose the condition in people, at least not in the early stages. However, the study uncovered a different, important connection. In men, higher levels of asporin in the blood were strongly linked to higher levels of alkaline phosphatase, a well-known enzyme that indicates active bone building. This link was not seen in women, suggesting that the body's response to fluoride and asporin might differ by sex.

The study concludes that fluoride triggers a specific chain reaction in bone cells that leads to an overproduction of asporin, driving the bone disease. While the protein itself may not yet be a perfect diagnostic tool for identifying patients in a clinic, the research provides a clear map of how the disease starts at a molecular level. It shows that the body's attempt to build bone in response to fluoride goes wrong because of a specific signaling error involving the Smad3 molecule. By identifying this pathway, the researchers have opened a door for future studies to see if blocking this signal could prevent or treat the disease. The findings also highlight that the relationship between fluoride, bone markers, and disease risk is complex and may look different in men and women, urging scientists to look closer at these individual differences in future research.